Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms CABOTHYROID
Most Recent Events
- 03 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 26 May 2023 Planned initiation date changed from 1 Apr 2023 to 1 May 2023.
- 26 May 2023 Status changed from not yet recruiting to recruiting.